RBC Capital maintains Insulet at Outperform, raises price target to $180 from $160

RBC Capital maintained its Outperform rating on Insulet and raised its price target to $180 from $160, citing a 9.1% upside from the Nov 4 close of $165.02. Recent analyst price targets for Insulet range from $150 to $200.

Original reporting
Published Nov 5, 2026, 7:28 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 5, 2026, 7:35 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
RBC Capital maintains Insulet at Outperform, raises price target to $180 from $160 — source image
Decision brief

The 30-second read

Low
01

Why it matters

Analyst price target increase signals confidence but lacks new operational data.

02

Market read

Analyst upgrade may modestly influence Insulet's stock price.

03

What to watch

Insulet's recent earnings and guidance remain unchanged.

Relevance 6/10Novelty 5/10Timing: today

Background

Insulet Corp. (ticker ISLE) designs and manufactures insulin infusion devices.

Market effects

May lift sentiment for diabetes device sector.

Limited to US healthcare equities.

Minimal

Counterpoint

Target raises can be premature if underlying fundamentals unchanged.

Key entities

  • RBC Capital

    Raised Insulet price target to $180.

Related articles

$PODDMedAI 8/10

Insulet Corp (PODD) Q3 2026 Earnings Call Highlights: Revenue Up 19%, EPS Jumps 60%

Insulet Corp (PODD) reported Q3 2026 revenue up 19% and EPS up 60%. US new customer starts were flat, while global growth was low single-digits. The company expects 2027 growth to be modestly below mid-teens due to tougher comparisons and increased competition. Free cash flow for 2026 is expected to be $275 million. PBM negotiations for 2027 are ongoing, creating some uncertainty. The company plans to launch Omnipod 6 in 2027, with features aimed at improving clinical outcomes and lifestyle fit.